MX2021015834A - Nuevas variantes de interleucina-2 para el tratamiento de cancer. - Google Patents

Nuevas variantes de interleucina-2 para el tratamiento de cancer.

Info

Publication number
MX2021015834A
MX2021015834A MX2021015834A MX2021015834A MX2021015834A MX 2021015834 A MX2021015834 A MX 2021015834A MX 2021015834 A MX2021015834 A MX 2021015834A MX 2021015834 A MX2021015834 A MX 2021015834A MX 2021015834 A MX2021015834 A MX 2021015834A
Authority
MX
Mexico
Prior art keywords
polypeptides
cancer
relates
present
diseases
Prior art date
Application number
MX2021015834A
Other languages
English (en)
Inventor
Yue-Sheng Li
Jing Xu
Lingyun Rui
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Publication of MX2021015834A publication Critical patent/MX2021015834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a polipéptidos que comparten la secuencia primaria con IL-2 humana, excepto por varios aminoácidos que se han mutado. Un panel de variantes de IL-2 comprende mutaciones que reducen sustancialmente la capacidad de estos polipéptidos para estimular los linfocitos Treg y hacerlos más eficaces en la terapia de tumores. Incluye también usos terapéuticos de estas variantes mutadas, utilizadas solas o en combinación con vacunas, o agentes biológicos dirigidos a TAA, o bloqueadores de puntos de control inmunitarios, o como el bloque de construcción en la construcción de moleculas bifuncionales, para la terapia de enfermedades tales como el cáncer o infecciones en donde la actividad de los linfocitos T reguladores (Tregs) es indeseable. En otro aspecto, la presente invención se refiere a composiciones farmacéuticas que comprenden los polipéptidos descritos. Finalmente, la presente invención se refiere al uso terapéutico de los polipéptidos y composiciones farmacéuticas descritos debido a su efecto modulador selectivo del sistema inmunológico sobre enfermedades tales como trastornos autoinmunitarios e inflamatorios, cáncer y diversas enfermedades infecciosas.
MX2021015834A 2019-06-14 2020-06-13 Nuevas variantes de interleucina-2 para el tratamiento de cancer. MX2021015834A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861651P 2019-06-14 2019-06-14
US201962947806P 2019-12-13 2019-12-13
PCT/US2020/037644 WO2020252418A2 (en) 2019-06-14 2020-06-13 Novel interleukin-2 variants for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021015834A true MX2021015834A (es) 2022-07-01

Family

ID=73782252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015834A MX2021015834A (es) 2019-06-14 2020-06-13 Nuevas variantes de interleucina-2 para el tratamiento de cancer.

Country Status (9)

Country Link
US (1) US20220235109A1 (es)
EP (1) EP3983433A4 (es)
JP (1) JP2022536345A (es)
KR (1) KR20220034115A (es)
CN (1) CN114651004A (es)
AU (1) AU2020291942A1 (es)
CA (1) CA3143034A1 (es)
MX (1) MX2021015834A (es)
WO (1) WO2020252418A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071013A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
CN111423510B (zh) * 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
WO2022050401A2 (en) * 2020-09-01 2022-03-10 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2024508949A (ja) * 2021-03-09 2024-02-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１標的化ｉｌ－２変異体イムノコンジュゲートとｆａｐ／４－１ｂｂ結合分子との併用療法
EP4304724A1 (en) * 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
BR112023019138A2 (pt) 2021-03-26 2023-10-24 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
CN117529504A (zh) 2021-06-09 2024-02-06 先天制药公司 结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
MX2024003535A (es) * 2021-09-22 2024-05-07 Fortvita Biologics Singapore Pte Ltd Proteina mutante de interleucina-2 y fusion de la misma.
WO2023076927A1 (en) * 2021-10-27 2023-05-04 Anwita Biosciences, Inc. Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2024104444A1 (zh) * 2022-11-17 2024-05-23 南通壹宸生物医药科技有限公司 Il-2突变体及其应用
WO2024199458A1 (en) * 2023-03-29 2024-10-03 Wuxi Biologics (Shanghai) Co., Ltd. Il-2 variants with improved stability and compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2005227263A1 (en) * 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
EA034925B1 (ru) * 2014-08-11 2020-04-07 Делиниа, Инк. Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN110382525B (zh) * 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
JP2021528105A (ja) * 2018-06-22 2021-10-21 キュージーン インコーポレイテッドＣｕｇｅｎｅ Ｉｎｃ． インターロイキン−２バリアントおよびその使用方法

Also Published As

Publication number Publication date
EP3983433A4 (en) 2023-08-09
EP3983433A2 (en) 2022-04-20
WO2020252418A3 (en) 2021-01-21
KR20220034115A (ko) 2022-03-17
JP2022536345A (ja) 2022-08-15
CN114651004A (zh) 2022-06-21
CA3143034A1 (en) 2020-12-17
US20220235109A1 (en) 2022-07-28
WO2020252418A2 (en) 2020-12-17
AU2020291942A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
PH12020500648A1 (en) Il-15 variants and uses thereof
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
WO2020252421A3 (en) Novel interleukin-2 variants and bifunctional fusion molecules thereof
WO2019099977A3 (en) Indole compounds as aryl hydrocarbon receptor (ahr) modulators
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
PH12021550872A1 (en) Therapeutic compounds
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
SA521421371B1 (ar) لقاحات الببتيد
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
WO2019160806A3 (en) Novel crystalline forms of tamibarotene for treatment of cancer
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
MX2021012543A (es) Compuestos de indoles quirales y su uso.
MX2021014353A (es) Adyuvantes de vacunas basados en ligandos de receptores tlr.
MX2023006294A (es) Proteinas de union a il-7 y su uso en tratamientos medicos.